The disease remains uniformly fatal because standard care has stalled.
For more than twenty years, glioblastoma has defied medicine's best efforts, offering patients a diagnosis that is swift, merciless, and nearly always fatal within fifteen months. Researchers at McMaster University have now engineered an immunotherapy that reprograms the body's own immune cells to dismantle not only the tumor itself but the biological scaffolding that allows it to survive and return — a distinction that may prove decisive. The therapy, built around a protein called uPAR, is drawing attention from leading cancer centers pursuing similar targets in other deadly cancers, and clinical trials are now within sight. It is, at its core, a story about science finally finding a new door in a room that has had no exits for a generation.
- Glioblastoma remains one of medicine's most stubborn failures — uniformly fatal, resistant to every standard weapon, and essentially untreated by any meaningful advance in over two decades.
- McMaster's uPAR CAR T cell therapy doesn't just target cancer cells — it goes after the surrounding support tissue that feeds tumor growth and enables it to regenerate after treatment, attacking the disease's survival strategy at its root.
- The convergence is striking: scientists at Memorial Sloan Kettering and Columbia University have independently zeroed in on uPAR as a target in lung and pancreatic cancers, lending the McMaster findings unexpected cross-institutional weight.
- The therapy has been patented and clinical trial discussions are already underway, with the team pursuing both commercial and human study pathways — though the translation from lab to patient could still take years.
- For first author William Maich, who has met glioblastoma patients through McMaster's bequeathal program, the science is inseparable from the human stakes — and the possibility of offering an alternative to current care carries the weight of those encounters.
Glioblastoma kills fast and without mercy. Tumors grow aggressively, shrug off surgery, radiation, and chemotherapy, and return even after exhaustive treatment. Median survival sits below fifteen months, and the standard of care today is essentially what it was twenty years ago — a fact that haunts every oncologist who treats the disease.
Researchers at McMaster University believe they may have found a way to break that stalemate. In preclinical work published in Science Translational Medicine, they demonstrated that a newly engineered immunotherapy can eliminate glioblastoma tumors in the laboratory — targeting not only the cancer cells themselves but the surrounding tissue that sustains and regenerates the tumor. The therapy, called a uPAR Chimeric CAR T cell, was developed using antibodies created in partnership with Canada's National Research Council and works by directing the body's own immune cells to attack a surface protein called uPAR, which appears on both the tumor and its biological scaffolding.
Principal investigator Sheila Singh, a professor in McMaster's Department of Surgery and a neuro-oncology specialist at King's College London, frames the work against a backdrop of urgent need. Standard treatment has stalled, she says, and the disease kills because medicine has run out of meaningful options. The McMaster findings are part of a broader scientific convergence: researchers at Memorial Sloan Kettering and Columbia University have independently identified uPAR as a promising target in lung and pancreatic cancers, opening the door to potential cross-cancer collaboration.
The therapy has been patented, and Singh's team is already in discussions about clinical trials, exploring both commercial and first-in-human study pathways. For postdoctoral fellow and lead author William Maich, the work carries a weight beyond the laboratory. Through McMaster's bequeathal program, he has come to know patients and families living under a diagnosis that offers almost no hope. Translating these preclinical results into something that could reach those patients, he says, would be a profound honour — and the first real possibility of change the disease has seen in a very long time.
Glioblastoma kills with a particular cruelty. The tumors grow fast, resist the standard arsenal of surgery, radiation, and chemotherapy, and come roaring back even after doctors have done everything they know how to do. Median survival from diagnosis is less than fifteen months. The disease remains uniformly fatal, and the treatments doctors use today are essentially the same ones they were using more than twenty years ago.
Now researchers at McMaster University say they may have found a way to change that. In preclinical research published in Science Translational Medicine, they demonstrated that a newly engineered immunotherapy can eliminate glioblastoma tumors in the laboratory—not just the cancer cells themselves, but also the supporting tissue that allows the disease to take root and persist. The drug candidate, called a uPAR Chimeric CAR T cell, represents a fundamentally different approach to a disease that has resisted conventional medicine for decades.
The therapy works by reprogramming the body's own immune system. Researchers, working with antibodies developed in partnership with Canada's National Research Council, engineered immune cells to recognize and attack a specific protein on the surface of glioblastoma cells called the urokinase receptor, or uPAR. What makes this approach distinctive is that uPAR also appears on the support cells surrounding the tumor—the biological scaffolding that feeds cancer growth and allows it to regenerate after treatment. By targeting both the cancer and its infrastructure, the therapy addresses a fundamental reason why glioblastoma is so difficult to defeat.
Sheila Singh, a professor in McMaster's Department of Surgery and the principal investigator on the study, emphasizes the urgency. "New therapies for glioblastoma are urgently needed," she says. The standard of care has stalled. The disease kills because medicine has run out of meaningful options. This work, she notes, is part of a broader convergence in cancer research. Scientists at Memorial Sloan Kettering and Columbia University have independently identified uPAR as a promising target in lung and pancreatic cancers. That convergence is already sparking collaborative efforts to develop therapies that might work across multiple hard-to-treat malignancies.
The research is not merely academic. Singh's lab, based at McMaster's Centre for Discovery in Cancer Research and supported by NexusHealth, is already in discussions about moving toward clinical trials. The therapy has been patented, and the team is exploring both commercial and clinical pathways. Singh, who also holds a position as professor of neuro-oncology and neurosurgery at King's College London, describes the candidate as "very exciting" and says the goal is to translate preclinical results into first-in-human studies.
For William Maich, a postdoctoral fellow in Singh's lab and first author on the study, the prospect carries personal weight. Maich has gotten to know glioblastoma patients and their families through McMaster's bequeathal program—a reminder that behind the science are people facing a diagnosis that offers almost no hope. "It would be a dream come true for me to have some of my work help glioblastoma patients," Maich says. "Being able to finally present them with an alternative to the current standard of care would be a great honour." The preclinical results are promising. What happens next depends on whether those results hold up when the therapy moves into human trials—a process that could take years, but represents the first real possibility of change in a disease that has remained essentially unchanged for two decades.
Notable Quotes
New therapies for glioblastoma are urgently needed. The standard of glioblastoma care has remained largely unchanged for over two decades, and the disease remains uniformly fatal because of it.— Sheila Singh, principal investigator, McMaster University
It would be a dream come true for me to have some of my work help glioblastoma patients. Being able to finally present them with an alternative to the current standard of care would be a great honour.— William Maich, postdoctoral fellow and first author, McMaster University
The Hearth Conversation Another angle on the story
Why does glioblastoma come back so aggressively after treatment?
Because doctors have only been attacking the tumor cells themselves. The cancer lives inside a kind of biological ecosystem—support cells that feed it, nurture it, help it hide. You can remove the tumor, blast it with radiation, poison it with chemotherapy, and the infrastructure is still there, waiting to rebuild.
And this uPAR protein—it's on both the cancer and the support cells?
Exactly. That's what makes it such an elegant target. You're not just killing cancer. You're dismantling the whole system that lets glioblastoma survive and come back.
How long before patients can actually receive this treatment?
That's the honest answer: we don't know yet. The preclinical work is done. Clinical trials are being discussed. But moving from the lab to human patients takes time—usually years. What matters is that there's finally a real candidate, a different approach, something that wasn't possible a few years ago.
What does it mean that other cancer centers are also pursuing uPAR?
It means this isn't a McMaster discovery in isolation. It's part of a larger recognition across top cancer research institutions that this protein is worth pursuing. That kind of convergence accelerates progress. It brings resources, collaboration, momentum.
For the researchers themselves, what's at stake?
For Maich especially, it's personal. He knows these patients. He's watched families navigate a diagnosis that offers almost no hope. The chance to offer them something different—that's not abstract to him. It's why he does the work.